Molecular Medicine SpA (MolMed) is an Italy-based medical biotechnology company focused on discovery, research and development, and clinical validation of therapies for the treatment of cancer. Its approach to cancer is based on an integrated strategy that provides both drugs targeting the growing tumor mass in the acute stage, and selective therapies to eliminate residual disease. MolMed is a drug company, and since July 2003, it is formally authorized to produce and release medicinal products for human use, in compliance with current Good Manufacturing Practice (GMP) standards. The Company has an in-house facility that meets both European and United States' GMP requirements.